Literature DB >> 28822973

PAI-1 levels are related to insulin resistance and carotid atherosclerosis in subjects with familial combined hyperlipidemia.

Arturo Carratala1, Sergio Martinez-Hervas2,3,4, Enrique Rodriguez-Borja1, Esther Benito3, José T Real2,3,4, Guillermo T Saez5,6, Rafael Carmena2,3, Juan F Ascaso2,3,4.   

Abstract

Familial combined hyperlipidemia (FCH) is a primary atherogenic dyslipidemia with insulin resistance and increased cardiovascular risk. Plasminogen activator inhibitor type 1 (PAI-1) and myeloperoxidase (MPO) activity are associated with proinflammatory and atherothrombotic risk. Our aim was to study the role played by PAI-1 and MPO activity in the carotid atherosclerosis prevalence in FCH subjects. 36 FCH unrelated subjects (17 women) were matched by age and body weight with 36 healthy normolipidemic subjects (19 female). Blood lipids, glucose, insulin, insulin resistance (homeostasis model assessment (HOMA)), MPO, and PAI-1 were determined in both groups. Carotid intima media thickness (IMT) was measured by the same investigator by standardized protocol. No differences in age, body mass index (BMI) or waist circumference were observed between the two groups. HOMA and PAI-1 values were higher in the FCH group, reaching statistical significance in those subjects with insulin resistance. In addition, PAI-1 values correlated significantly with metabolic syndrome components and carotid IMT. It is known that the elevated cardiovascular risk that characterizes FCH is frequently associated with insulin resistance. We have detected that two known proinflammatory and proatherothrombotic factors (MPO and PAI-1) are significantly elevated in FCH subjects with insulin resistance. These results could partly explain the high cardiovascular risk present in FCH subjects. © American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  PAI-1; familial combined hyperlipidemia; insulin resistance; myeloperoxidase.

Mesh:

Substances:

Year:  2017        PMID: 28822973     DOI: 10.1136/jim-2017-000468

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  6 in total

1.  Prognostic Significance of Plasma Insulin Level for Deep Venous Thrombosis in Patients with Severe Traumatic Brain Injury in Critical Care.

Authors:  Min Du; Qing-Hong Zhang; Rui Tang; Hai-Yan Liu; Zong-Shu Ji; Zhi Gao; Ying Wang; He-Yang You; Ji-Wei Hao; Min Zhou
Journal:  Neurocrit Care       Date:  2022-09-16       Impact factor: 3.532

2.  Associations among serum insulin, calprotectin, and C-reactive protein concentrations in Miniature Schnauzers with idiopathic hyperlipidemia before and after feeding an ultra-low-fat diet.

Authors:  Panagiotis G Xenoulis; Romy M Heilmann; Eva M Stavroulaki; Denise S Riggers; Laura J Gneipel; Jan S Suchodolski; Jörg M Steiner
Journal:  J Vet Intern Med       Date:  2022-04-21       Impact factor: 3.175

3.  The relationship of mesencephalic astrocyte-derived neurotrophic factor with hyperlipidemia in patients with or without type 2 diabetes mellitus.

Authors:  Jili Fu; Kija Malale; Xie Luo; Min Chen; Qicong Liu; Wei Cheng; Dongfang Liu
Journal:  Hormones (Athens)       Date:  2021-02-08       Impact factor: 2.885

Review 4.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

5.  SerpinE1 drives a cell-autonomous pathogenic signaling in Hutchinson-Gilford progeria syndrome.

Authors:  Chiara Nicoletti; Andrea Bracaglia; Giorgia Catarinella; Paola Procopio; Illari Salvatori; Marilena Taggi; Cristiana Valle; Alberto Ferri; Rita Canipari; Pier Lorenzo Puri; Lucia Latella
Journal:  Cell Death Dis       Date:  2022-08-26       Impact factor: 9.685

Review 6.  A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.